Soleno Therapeutics Inc (SLNO) Stock Analysis

Soleno Therapeutics Inc (SLNO) is a publicly traded company in the HEALTHCARE sector. It trades at $53.01. This page summarizes the public market data, fundamentals, and frequently asked questions for SLNO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $53.01

Market Sentiment

Soleno Therapeutics Inc currently has a Neutral sentiment score of -0.13.

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing novel therapies for rare diseases. The company utilizes its proprietary drug development platform to bring innovative treatments through clinical trials, effectively addressing significant unmet medical needs in this specialized market. Soleno's dedication to pioneering therapeutic solutions, combined with its strategic positioning in the rare disease sector...

GNG Research Analysis

GNG Research scores Soleno Therapeutics Inc (SLNO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SLNO.

Frequently Asked Questions

Does SLNO pay dividends?

Soleno Therapeutics Inc (SLNO) does not currently pay a regular dividend.